Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland ; volume:13 ; number:1 ; day:28 ; month:9 ; year:2022 ; pages:1-10 ; date:12.2022
Nature Communications ; 13, Heft 1 (28.9.2022), 1-10, 12.2022
- Urheber
-
Norddahl, Gudmundur L.
Melsted, Pall
Gunnarsdottir, Kristbjorg
Halldorsson, Gisli H.
Olafsdottir, Thorunn A.
Gylfason, Arnaldur
Kristjansson, Mar
Magnusson, Olafur T.
Sulem, Patrick
Gudbjartsson, Daniel F.
Thorsteinsdottir, Unnur
Jonsdottir, Ingileif
Stefansson, Kari
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-022-33076-4
- URN
-
urn:nbn:de:101:1-2022121621040380811715
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Norddahl, Gudmundur L.
- Melsted, Pall
- Gunnarsdottir, Kristbjorg
- Halldorsson, Gisli H.
- Olafsdottir, Thorunn A.
- Gylfason, Arnaldur
- Kristjansson, Mar
- Magnusson, Olafur T.
- Sulem, Patrick
- Gudbjartsson, Daniel F.
- Thorsteinsdottir, Unnur
- Jonsdottir, Ingileif
- Stefansson, Kari
- SpringerLink (Online service)
Ähnliche Objekte (12)
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Clinical characteristics and booster vaccine effectiveness of the Omicron variant